Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05209776
Recruiting Not applicable

Local Inflammation in Arrhythmogenic Right Ventricular Cardiomyopathy

NCT05209776 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Toulouse
Phase
Not applicable
Started
2022-02-01
Last updated
2026-06-01

Condition(s) studied

Arrhythmogenic Right Ventricular Dysplasia

Investigational drug(s) / intervention(s)

Peripheral immunological assessment on venous bloodImmunological assessment carried out on intracardiac material

Peripheral immunological assessment on venous blood: Peripheral immunological assessment carried out as part of the research, on venous blood at the puncture point necessary for the electrophysiological examination: 1 heparin tube and 1 EDTA tube

Immunological assessment carried out on intracardiac material: Immunological assessment carried out as part of the research, on intracardiac material taken during the electrophysiological examination: 1 EDTA tube

Study summary

The understanding of ARVC pathophysiology remains incomplete. Several clues indicate that disease progression is mediated through inflammation. The present study aim to document the feasibility of detecting the potential presence of intracardiac local inflammatory components in patients with ARVC.

Eligibility

Sex
ALL
Min age
18 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria: * For cases: * Arrhythmogenic right ventricular dysplasia diagnosed (according to 2010 Task Force Criteria) * Admitted for right ventricle electrophysiologic mapping * For controls \* Admitted for ablation procedures (accessory pathway, atrial flutter) on otherwise healthy hearts. Exclusion Criteria: * Diagnostic of systemic chronic inflammatory disease * Presence of possible or proven cardiac involvement of an inflammatory disease, an acute or chronic infectious disease. * Taking immunosuppressant or immunomodulating medications

Primary outcome measure(s)

  • Identify the inflammatory components by C-reactive protein — 24 months
    Rate of C-reactive protein in the blood
  • Identify the inflammatory components by interleukine1 — 24 months
    Rate of interleukin 1 beta in the blood
  • Identify the inflammatory components by onterleukine6 — 24 months
    Rate of interleukin 6 in the blood
  • Identify the inflammatory components by interleukine10 — 24 months
    Rate of interleukin 10 in the blood
  • Identify the inflammatory components by Tumor Necrosis Factor — 24 months
    Rate of Tumor Necrosis Factor alpha in the blood
  • Identify the inflammatory components by Transforming Growth Factor — 24 months
    Rate of Transforming Growth Factor beta in the blood

Trial sites (1)

FacilityCityRegionStatus
Toulouse University Hospital Center Toulouse France Recruiting

More University Hospital, Toulouse trials in France

Intragastric Balloon in Obese Patients With Uncontrolled Asthma Recruiting
Study of the Interprofessional Reproducibility of a Clinical Observation Scale for the Development of Very Premature Infants Starting soon
Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney Involvement Starting soon
LUng and Cardiac Ultrasound for REspiratory Distress in ElDerly Recruiting
Semantic Rehabilitation for Patients With Primary Progressive Semantic Aphasia Recruiting

Other trials for the same condition

Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05209776 on ClinicalTrials.gov ↗ ← All trials in France